Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I think in this new climate, it's buy out or be bought out, I think in our position either is good and possible. Absorbing the competition or getting absorbed by a parent.
JTFM- If I'm not mistaken, I thought blackrock increased their stake pretty recently? You're right, the volume is a pittance in the face of the reaction. And we've recently had worse in face of less. Also, the volume leading up to this point has been pretty abysmally low too.
I'm equally unhappy about this, and I'd love for Art to attract more investors, but hopefully he's playing a long game here that we longs can't appreciate from our perspective.
Short interest has been pretty low- 7.33% as of mid feb- I thought that'd be a good thing, but I'm sure in the next few weeks/months, this will rise accordingly.
-RG
I've never found a link that has historic SI. I've been pulling the numbers from the vitals noted on market watch. Every 2 weeks it updates revealing the prior two weeks SI. I cross reference the price on the date.
If anyone has another way to collect this data, I'd be interested to see the historic tracking prior to the start of this year (when I started archiving these numbers).
RG
I think you're right- the pattern has been consistent over the past few years- I've seen it as an ECG readout- peaks and troughs with a flat line in between.
RG
On that note- short interest is up:
09/30/19
Short Interest: 1.49M
% of Float Shorted: 16.23%
Share Price: $72.88
09/13/19
Short Interest: 1.25M
% of Float Shorted: 13.62%
Share Price: $76.53
08/30/19
Short Interest: 1.13M
% of Float Shorted: 12.40%
Share Price: $65.50
08/15/19
Short Interest: 1.39M
% of Float Shorted: 15.23%
Share Price: $67.09
07/31/19 (QE 8/7/19)
Short Interest: 1.49M
% of Float Shorted: 16.89%
Share Price: $84.59
07/15/19
Short Interest: 1.4M
% of Float Shorted: 15.89%
Share Price: $80.80
06/28/19
Short Interest: 1.22M
% of Float Shorted: 13.83%
Share Price: $82.20
06/14/19
Short Interest: 1.13M
% of Float Shorted: 12.80%
Share Price: $70.54
05/31/19
Short Interest: 1.09M
% of Float Shorted: 12.36%
Share Price: $69.66
05/15/19
Short Interest: 1.18M
% of Float Shorted: 13.43%
Share Price: $69.14
04/30/19
Short Interest: 1.14M
% of Float Shorted: 12.96%
Share Price: $70.98
04/15/19 (QE 03/31/19)
Short Interest: 1.03M
% of Float Shorted: 11.77%
Share Price: $68.45
03/15/19
Short Interest: 889.44K
% of Float Shorted: 10.11%
Share Price: $63.49
02/28/19
Short Interest: 835.63K
% of Float Shorted: 9.5%
Share Price: $65.79
01/31/19
Short Interest: 694.71K
% of Float Shorted: 7.90%
Share Price: $53.74
01/15/19
Short Interest: 738.09K
% of Float Shorted: 8.39%
Share Price: $53.17
-RG
Short Interest up a bit:
09/13/19
Short Interest: 1.25M
% of Float Shorted: 13.62%
Share Price: $76.53
08/30/19
Short Interest: 1.13M
% of Float Shorted: 12.40%
Share Price: $65.50
08/15/19
Short Interest: 1.39M
% of Float Shorted: 15.23%
Share Price: $67.09
07/31/19 (QE 8/7/19)
Short Interest: 1.49M
% of Float Shorted: 16.89%
Share Price: $84.59
07/15/19
Short Interest: 1.4M
% of Float Shorted: 15.89%
Share Price: $80.80
06/28/19
Short Interest: 1.22M
% of Float Shorted: 13.83%
Share Price: $82.20
06/14/19
Short Interest: 1.13M
% of Float Shorted: 12.80%
Share Price: $70.54
05/31/19
Short Interest: 1.09M
% of Float Shorted: 12.36%
Share Price: $69.66
05/15/19
Short Interest: 1.18M
% of Float Shorted: 13.43%
Share Price: $69.14
04/30/19
Short Interest: 1.14M
% of Float Shorted: 12.96%
Share Price: $70.98
04/15/19 (QE 03/31/19)
Short Interest: 1.03M
% of Float Shorted: 11.77%
Share Price: $68.45
03/15/19
Short Interest: 889.44K
% of Float Shorted: 10.11%
Share Price: $63.49
02/28/19
Short Interest: 835.63K
% of Float Shorted: 9.5%
Share Price: $65.79
01/31/19
Short Interest: 694.71K
% of Float Shorted: 7.90%
Share Price: $53.74
01/15/19
Short Interest: 738.09K
% of Float Shorted: 8.39%
Share Price: $53.17
-RG
Positive results on Cortrophin. News hasn't done anything to the stock price- suspect this a smaller step in the process with the small study size and focus on assessing steady state in the blood.
BAUDETTE, Minn., Oct. 3, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the receipt of clinical data on Cortrophin® Gel (80 units/mL) from a study that evaluated the blood-level cortisol response in a 20-person healthy volunteer population.
Key results:
The results indicate that ANI's Cortrophin® Gel (80 units/mL) is effective for its intended use.
In addition, the clinical data demonstrate that ANI's modernized Cortrophin® Gel (80 units/mL) drug product has a cortisol response profile consistent with that observed in historical scientific literature that evaluated Cortrophin® Gel (44 units/mL) drug product manufactured in the 1960s (Brombacher et. al, 1969).
No adverse safety events to be reported and minor events were as expected.
The final data set from this study will be locked on October 25, 2019.
Arthur S. Przybyl, ANI's President and CEO commented, "These results represent a significant milestone for ANI in our re-commercialization effort for Cortrophin® Gel. In conjunction with our positive results in process and product characterization at commercial scale, method development and validation, release of clinical material and viral clearance, I believe this study demonstrates that we have successfully reproduced the Cortrophin® Gel drug previously manufactured in the 1990s. As such, I believe we will have an approvable drug product. We are excited to submit the Cortrophin® Gel comprehensive supplemental NDA filing currently planned for March 2020."
About Purified Cortrophin® Gel
Cortrophin® Gel is purified corticotropin (ATCH) manufactured in sterile gelatin to allow prolonged activity. The product stimulates the functioning adrenal cortex to produce and secrete adrenocortical hormones.
For more information, including the complete list of indications and usages, please see the Full Prescribing Information.
-RG
A significant drop in Short Interest:
08/30/19
Short Interest: 1.13M
% of Float Shorted: 12.40%
Share Price: $65.50
08/15/19
Short Interest: 1.39M
% of Float Shorted: 15.23%
Share Price: $67.09
07/31/19 (QE 8/7/19)
Short Interest: 1.49M
% of Float Shorted: 16.89%
Share Price: $84.59
07/15/19
Short Interest: 1.4M
% of Float Shorted: 15.89%
Share Price: $80.80
06/28/19
Short Interest: 1.22M
% of Float Shorted: 13.83%
Share Price: $82.20
06/14/19
Short Interest: 1.13M
% of Float Shorted: 12.80%
Share Price: $70.54
05/31/19
Short Interest: 1.09M
% of Float Shorted: 12.36%
Share Price: $69.66
05/15/19
Short Interest: 1.18M
% of Float Shorted: 13.43%
Share Price: $69.14
04/30/19
Short Interest: 1.14M
% of Float Shorted: 12.96%
Share Price: $70.98
04/15/19 (QE 03/31/19)
Short Interest: 1.03M
% of Float Shorted: 11.77%
Share Price: $68.45
03/15/19
Short Interest: 889.44K
% of Float Shorted: 10.11%
Share Price: $63.49
02/28/19
Short Interest: 835.63K
% of Float Shorted: 9.5%
Share Price: $65.79
01/31/19
Short Interest: 694.71K
% of Float Shorted: 7.90%
Share Price: $53.74
01/15/19
Short Interest: 738.09K
% of Float Shorted: 8.39%
Share Price: $53.17
-RG
Short Interest dropped:
08/15/19
Short Interest: 1.39M
% of Float Shorted: 15.23%
Share Price: $67.09
07/31/19 (QE 8/7/19)
Short Interest: 1.49M
% of Float Shorted: 16.89%
Share Price: $84.59
07/15/19
Short Interest: 1.4M
% of Float Shorted: 15.89%
Share Price: $80.80
06/28/19
Short Interest: 1.22M
% of Float Shorted: 13.83%
Share Price: $82.20
06/14/19
Short Interest: 1.13M
% of Float Shorted: 12.80%
Share Price: $70.54
05/31/19
Short Interest: 1.09M
% of Float Shorted: 12.36%
Share Price: $69.66
05/15/19
Short Interest: 1.18M
% of Float Shorted: 13.43%
Share Price: $69.14
04/30/19
Short Interest: 1.14M
% of Float Shorted: 12.96%
Share Price: $70.98
04/15/19 (QE 03/31/19)
Short Interest: 1.03M
% of Float Shorted: 11.77%
Share Price: $68.45
03/15/19
Short Interest: 889.44K
% of Float Shorted: 10.11%
Share Price: $63.49
02/28/19
Short Interest: 835.63K
% of Float Shorted: 9.5%
Share Price: $65.79
01/31/19
Short Interest: 694.71K
% of Float Shorted: 7.90%
Share Price: $53.74
01/15/19
Short Interest: 738.09K
% of Float Shorted: 8.39%
Share Price: $53.17
-RG
Meridian Venture Partners II LP sold 61,697 shares over Friday, yesterday, and today, averaging around 71.60. It's around 2.7% of what they own...
RG
Short Interest up another percent. I suspect next SI report will be static or start to drop again.
07/31/19 (QE 8/7/19)
Short Interest: 1.49M
% of Float Shorted: 16.89%
Share Price: $84.59
07/15/19
Short Interest: 1.4M
% of Float Shorted: 15.89%
Share Price: $80.80
06/28/19
Short Interest: 1.22M
% of Float Shorted: 13.83%
Share Price: $82.20
06/14/19
Short Interest: 1.13M
% of Float Shorted: 12.80%
Share Price: $70.54
05/31/19
Short Interest: 1.09M
% of Float Shorted: 12.36%
Share Price: $69.66
05/15/19
Short Interest: 1.18M
% of Float Shorted: 13.43%
Share Price: $69.14
04/30/19
Short Interest: 1.14M
% of Float Shorted: 12.96%
Share Price: $70.98
04/15/19 (QE 03/31/19)
Short Interest: 1.03M
% of Float Shorted: 11.77%
Share Price: $68.45
03/15/19
Short Interest: 889.44K
% of Float Shorted: 10.11%
Share Price: $63.49
02/28/19
Short Interest: 835.63K
% of Float Shorted: 9.5%
Share Price: $65.79
01/31/19
Short Interest: 694.71K
% of Float Shorted: 7.90%
Share Price: $53.74
01/15/19
Short Interest: 738.09K
% of Float Shorted: 8.39%
Share Price: $53.17
-RG
haha- I saw that too- but I think I saw that price as an ask after closing ($85.50)- could be someone bought at the ask price? Ask right now is at 90 bucks. I'm looking forward to tomorrow, maybe narrow down timelines...maybe speak to libigel...one can only hope.
GLTA tomorrow and thereafter.
-RG
Addendum:
Just checked- apparently 410 shares traded over the course of an hour starting at 1900 ET. 290 of those were traded at 85.50, the rest at 85.28.
It's rising quite a bit- up 2% since reported two weeks ago.
JTFM, I agree they hold their own shares to cover. It seems it's a repeatable cycle. Given the recent rise in shorts, I worry they'll control it back down to cover as they had in the past, but I also believe it will still continue north in the long run.
With respect to broaching the 1bil market cap and new investors entering- when do they report that information? Post earnings? Anyone have a pulse on the institutions coming and going, loading or dumping?
I've only started tracking this information this year, anyone have access to the historic numbers on this? Maybe extract a pattern to this behavior? Or is this just a different approach at staring into the same crystal ball?
07/15/19
Short Interest: 1.4M
% of Float Shorted: 15.89%
Share Price: $80.80
06/28/19
Short Interest: 1.22M
% of Float Shorted: 13.83%
Share Price: $82.20
06/14/19
Short Interest: 1.13M
% of Float Shorted: 12.80%
Share Price: $70.54
05/31/19
Short Interest: 1.09M
% of Float Shorted: 12.36%
Share Price: $69.66
05/15/19
Short Interest: 1.18M
% of Float Shorted: 13.43%
Share Price: $69.14
04/30/19
Short Interest: 1.14M
% of Float Shorted: 12.96%
Share Price: $70.98
04/15/19
Short Interest: 1.03M
% of Float Shorted: 11.77%
Share Price: $68.45
03/15/19
Short Interest: 889.44K
% of Float Shorted: 10.11%
Share Price: $63.49
02/28/19
Short Interest: 835.63K
% of Float Shorted: 9.5%
Share Price: $65.79
01/31/19
Short Interest: 694.71K
% of Float Shorted: 7.90%
Share Price: $53.74
01/15/19
Short Interest: 738.09K
% of Float Shorted: 8.39%
Share Price: $53.17
-RG
jeffqdhsr, Art told me the same thing- very specifically said they wouldn't move forward on it without a partner-and there wasn't anyone interested in partnering or buying it from them at that time. I was surprised by his honesty. The way he made it sound, it was an asset associated with the merger but required more investment than he was willing to make. My conversation was a few years back as well.
From what I understand, I don't believe they've taken any steps forward on it. I tried reaching back out to him last December but always found my way to investor relations who simply referred me back to their website for answers to my questions. I recall them flat out refusing to answer any questions on libigel specifically, I took that as a positive given his openness ealier.
Congrats everyone, long time coming is an understatement.
-RG
Apparently all generic drug makers were down today
Sympathy Drop
-RG
One percent rise in short interest. May speak to the slow roll down the hill in the share price seen recently- but looking back at May, I don't think we'll see the extreme swings we've experienced in the past. Or maybe it's wishful thinking.
06/28/19
Short Interest: 1.22M
% of Float Shorted: 13.83%
Share Price: $82.20
06/14/19
Short Interest: 1.13M
% of Float Shorted: 12.80%
Share Price: $70.54
05/31/19
Short Interest: 1.09M
% of Float Shorted: 12.36%
Share Price: $69.66
05/15/19
Short Interest: 1.18M
% of Float Shorted: 13.43%
Share Price: $69.14
04/30/19
Short Interest: 1.14M
% of Float Shorted: 12.96%
Share Price: $70.98
04/15/19
Short Interest: 1.03M
% of Float Shorted: 11.77%
Share Price: $68.45
03/15/19
Short Interest: 889.44K
% of Float Shorted: 10.11%
Share Price: $63.49
02/28/19
Short Interest: 835.63K
% of Float Shorted: 9.5%
Share Price: $65.79
01/31/19
Short Interest: 694.71K
% of Float Shorted: 7.90%
Share Price: $53.74
01/15/19
Short Interest: 738.09K
% of Float Shorted: 8.39%
Share Price: $53.17
-RG
Wow! Congrats everyone- Finally broke $80!
-RG
Short Interest rose a bit:
06/14/19
Short Interest: 1.13M
% of Float Shorted: 12.80%
Share Price: $70.54
05/31/19
Short Interest: 1.09M
% of Float Shorted: 12.36%
Share Price: $69.66
05/15/19
Short Interest: 1.18M
% of Float Shorted: 13.43%
Share Price: $69.14
04/30/19
Short Interest: 1.14M
% of Float Shorted: 12.96%
Share Price: $70.98
04/15/19
Short Interest: 1.03M
% of Float Shorted: 11.77%
Share Price: $68.45
03/15/19
Short Interest: 889.44K
% of Float Shorted: 10.11%
Share Price: $63.49
02/28/19
Short Interest: 835.63K
% of Float Shorted: 9.5%
Share Price: $65.79
01/31/19
Short Interest: 694.71K
% of Float Shorted: 7.90%
Share Price: $53.74
01/15/19
Short Interest: 738.09K
% of Float Shorted: 8.39%
Share Price: $53.17
-RG
Not a slam dunk on HSDD, a little different than libigel- the population group is different, chemistry, mode of action, application too...okay, quite a bit different, but hopefully it renews the conversation over at Anip.
"The effectiveness and safety of Vyleesi were studied in two 24-week, randomized, double-blind, placebo-controlled trials in more than 1,200 premenopausal women with HSDD.
Most patients used Vyleesi two or three times per month and no more than once a week. In these trials, about 25 percent of patients treated with Vyleesi had an increase in their sexual desire score, compared to about 17 percent of those who took a placebo.
About 35 percent of the patients treated with Vyleesi had a decrease of one or more in their distress score, compared to about 31 percent of those who took a placebo, the FDA said. Side effects during the trial included headaches, flushing and nausea.
Initial consumer uptake of Vyleesi is expected to be slow, according to industry analysts. But some expect revenue to increase significantly over time, hitting as much as $150 million by 2030, according to Barclays."
-RG
If memory serves me, I think the all time high under Anip was 75? Maybe 2 years ago? Frustrating to know how much they've accomplished in this period of time and we've arrived back to a similar high.
-RG
Thanks JTFM- oddly enough when I looked up the corporate presentations on their website, I only saw the yearly ones from June for 17, 18, and 19. Thanks for the link
-RG
The share price remains high despite the drop as well.
I recall heading into their summer investor presentations in the past, not a whole lot comes from it with respect to vol/share price, but this seems different, I think slapping the nda badge for cortrophin gel for 1q2020 on their presentation may help shift the running theme we've seen in the past (I don't recall seeing it on past presentations). We're up more than 2% today at the time of posting this.
-RG
Short interest dropped a bit.
05/31/19
Short Interest: 1.09M
% of Float Shorted: 12.36%
Share Price: $69.66
05/15/19
Short Interest: 1.18M
% of Float Shorted: 13.43%
Share Price: $69.14
04/30/19
Short Interest: 1.14M
% of Float Shorted: 12.96%
Share Price: $70.98
04/15/19
Short Interest: 1.03M
% of Float Shorted: 11.77%
Share Price: $68.45
03/15/19
Short Interest: 889.44K
% of Float Shorted: 10.11%
Share Price: $63.49
02/28/19
Short Interest: 835.63K
% of Float Shorted: 9.5%
Share Price: $65.79
01/31/19
Short Interest: 694.71K
% of Float Shorted: 7.90%
Share Price: $53.74
01/15/19
Short Interest: 738.09K
% of Float Shorted: 8.39%
Share Price: $53.17
-RG
Here's the presentation:
Corporate Presentation June 2019
-RG
Nash also apparently has impeccable timing.
-RG
05/15/19
Short Interest: 1.18M
% of Float Shorted: 13.43%
04/30/19
Short Interest: 1.14M
% of Float Shorted: 12.96%
Share Price: $70.98
04/15/19
Short Interest: 1.03M
% of Float Shorted: 11.77%
Share Price: $68.45
03/15/19
Short Interest: 889.44K
% of Float Shorted: 10.11%
Share Price: $63.49
02/28/19
Short Interest: 835.63K
% of Float Shorted: 9.5%
Share Price: $65.79
01/31/19
Short Interest: 694.71K
% of Float Shorted: 7.90%
Share Price: $53.74
01/15/19
Short Interest: 738.09K
% of Float Shorted: 8.39%
Share Price: $53.17
-RG
Director Nash bought 1445 shares on the open market @ $68.76. He only holds 5236 shares...odd?
RG
Short interest continues to climb.
04/30/19
Short Interest: 1.14M
% of Float Shorted: 12.96%
Share Price: $70.98
04/15/19
Short Interest: 1.03M
% of Float Shorted: 11.77%
Share Price: $68.45
03/15/19
Short Interest: 889.44K
% of Float Shorted: 10.11%
Share Price: $63.49
02/28/19
Short Interest: 835.63K
% of Float Shorted: 9.5%
Share Price: $65.79
01/31/19
Short Interest: 694.71K
% of Float Shorted: 7.90%
Share Price: $53.74
01/15/19
Short Interest: 738.09K
% of Float Shorted: 8.39%
Share Price: $53.17
-RG
Good news does very little while any scent of bad tends to bring this down- I'm happily surprised that the recent selling hasn't negatively impacted our momentum.
RG
It went up and Zack's was busy pumping out fluff articles articles daily up until last week, when they downgraded it from a buy to a hold...which isn't surprising given earnings is this week. Mind you, I very much want to be wrong, and that we take off May 9th...but fool me fifteen times...
04/15/19
Short Interest: 1.03M
% of Float Shorted: 11.77%
Share Price: $68.45
03/15/19
Short Interest: 889.44K
% of Float Shorted: 10.11%
Share Price: $63.49
02/28/19
Short Interest: 835.63K
% of Float Shorted: 9.5%
Share Price: $65.79
01/31/19
Short Interest: 694.71K
% of Float Shorted: 7.90%
Share Price: $53.74
01/15/19
Short Interest: 738.09K
% of Float Shorted: 8.39%
Share Price: $53.17
-RG
Short Interest has risen 2.2% over the course of the past month and a half--in line with the rise in share price over the same period.
03/15/19
Short Interest: 889.44K
% of Float Shorted: 10.11%
Share Price: $63.49
02/28/19
Short Interest: 835.63K
% of Float Shorted: 9.5%
Share Price: $65.79
01/31/19
Short Interest: 694.71K
% of Float Shorted: 7.90%
Share Price: $53.74
01/15/19
Short Interest: 738.09K
% of Float Shorted: 8.39%
Share Price: $53.17
Zacks put ANIP as a buy today:
https://www.zacks.com/commentary/365268/new-strong-buy-stocks-for-march-28th?cid=CS-MKTWTCH-HL-365268&mod=mw_quote_news
I've been here long enough to worry about the cycle repeating-a pump and dump despite strong fundamentals.
GLTA
RG
At the time of posting this 18.5k shares have been traded and it's gone up by 15 cents...can anyone shed some light on how that works?
Thanks
-RG
Thanks for the correction and links. I don't know what more needed to be concealed behind the devastating news that day--but whatever it is, they still want it kept quiet.
RG
Renewed a confidential treatment order from the merger in 2012???
February 22, 2019
ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES ACT OF 1933
ANI Pharmaceuticals, Inc.File No. 333-185391 - CF#37061
ANI Pharmaceuticals, Inc. (formerly BioSante Pharmaceuticals, Inc.) submitted an application under Rule 406 requesting an extension of a previous grant of confidential treatment for information it excluded from the Exhibits to a Form S-4 registration statement filed on December 11, 2012.
Based on representations by ANI Pharmaceuticals, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it.
Accordingly, excluded information from the following exhibits will not be released to the public for the time period specified:
Exhibit 10.55through December 11, 2021 (From the first Ct order)
Exhibit 10.57through December 11, 2021 (From the first Ct order)
Exhibit 10.60through February 5, 2024 (From the second Ct order)
For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:
Brent J. Fields
Secretary
RG
It's working for me- probably just a some gunk in the tubes.
RG
Short Interest has dropped:
01/31/19
Short Interest: 694.71K
% of Float Shorted: 7.90%
01/15/19
Short Interest: 738.09K
% of Float Shorted: 8.39%
RG
On January 30, 2019, ANI Pharmaceuticals, Inc. (the “Company”) entered into Amendment No. 4 to its Asset Purchase Agreement (the “Purchase Agreement Amendment”) with Teva Pharmaceuticals USA, Inc. (“Teva”). Under the terms of the Purchase Agreement Amendment, all royalty obligations of the Company owed to Teva with respect to products associated with ten ANDAs under the Asset Purchase Agreement shall cease effective as of December 31, 2018. In consideration for the termination of such future royalty obligations, the Company agreed to pay Teva a sum of $16,000,000.
RG
Kick up or down? Eliminating backdoor rebates will force the consumer to pay more for branded drugs, putting pressure on either dropping prices or forcing the consumer to switch to generics. I see it good in the long term, but I fear the entire sector will fall given the news, including us.
...But I'm pessimistic though- we've been stuck treading water for nearly a year and I'm waiting on baited breath for something to actually kick this thing in high gear. The volume has been shockingly low the past few sessions and I don't understand why there isn't more interest.
RG
Percent floated seems minimally changed since what was reported in December:
01/15/19
Short Interest: 738.09K
% of Float Shorted: 8.39%
RG
I guess they sold some at the end of September- 4,820.
Not sure why they would given that's a pretty insignificant amount (0.35%).
This article came out the other day:
BlackRock Inc. cut its holdings in shares of ANI Pharmaceuticals Inc (NASDAQ:ANIP) by 0.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,386,354 shares of the specialty pharmaceutical company’s stock after selling 4,820 shares during the quarter. BlackRock Inc. owned 11.72% of ANI Pharmaceuticals worth $78,384,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also made changes to their positions in the company. Teachers Retirement System of The State of Kentucky increased its holdings in shares of ANI Pharmaceuticals by 99.5% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 2,005 shares of the specialty pharmaceutical company’s stock worth $113,000 after purchasing an additional 1,000 shares during the period. Thomson Horstmann & Bryant Inc. increased its holdings in shares of ANI Pharmaceuticals by 5.3% during the third quarter. Thomson Horstmann & Bryant Inc. now owns 25,156 shares of the specialty pharmaceutical company’s stock worth $1,422,000 after purchasing an additional 1,258 shares during the period. Strs Ohio increased its holdings in shares of ANI Pharmaceuticals by 10.7% during the third quarter. Strs Ohio now owns 13,500 shares of the specialty pharmaceutical company’s stock worth $763,000 after purchasing an additional 1,300 shares during the period. Legal & General Group Plc increased its holdings in shares of ANI Pharmaceuticals by 8.0% during the second quarter. Legal & General Group Plc now owns 17,876 shares of the specialty pharmaceutical company’s stock worth $1,198,000 after purchasing an additional 1,318 shares during the period. Finally, Rhumbline Advisers increased its holdings in shares of ANI Pharmaceuticals by 6.8% during the second quarter. Rhumbline Advisers now owns 21,866 shares of the specialty pharmaceutical company’s stock worth $1,461,000 after purchasing an additional 1,399 shares during the period. 63.23% of the stock is currently owned by institutional investors.
-RG